---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-026723"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2024-07-10T23:59:59+00:00"
generated_at: "2026-05-31T22:10:01.987205+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Nasdaq panel grants Vivos continued listing subject to filing Q2 Form 10-Q by Aug 15, 2024

## Summary
- Panel granted continued listing on Nasdaq conditional on filing Form 10-Q for quarter ended June 30, 2024 by August 15, 2024.
- Company must evidence stockholders' equity of at least $2.5 million in the Form 10-Q.
- Exploring additional equity financing to maintain compliance with Nasdaq equity requirement.
- Risk of delisting if compliance not achieved; delisting would materially harm stock price and capital access.

## SEC filing metadata
- accession: 0001493152-24-026723
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2024-07-10T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315224026723/0001493152-24-026723-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315224026723/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-026723
- JSON: https://secwatch.observer/filing/0001493152-24-026723.json
- Plain text: https://secwatch.observer/filing/0001493152-24-026723.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.